Is Peptide Therapy Covered by Insurance?

General information for practice owners, not medical, legal or tax advice.

The caller is not asking about science. She is asking whether her card gets declined.

"Is peptide therapy covered by insurance" is one of the most common questions a longevity clinic hears before a first appointment, and the honest answer is almost always no. Not because a payer made a judgment call about peptides, but because of how the U.S. Food and Drug Administration, the Centers for Medicare and Medicaid Services, and commercial payers define what a covered drug is in the first place. Section 503A of the Federal Food, Drug, and Cosmetic Act governs which bulk substances a pharmacy may compound. Medicare Part D defines what counts as a Part D drug. Cigna Coverage Policy IP0251 defines what a compounded medication has to contain to be considered at all. BPC-157, ipamorelin and CJC-1295 do not clear those definitions. Tesamorelin, sold as EGRIFTA, does.

This piece lays out the mechanism, cites the source documents, and separates what actually changed in 2026 from what the internet says changed.

The short answer: compounded peptides are almost never covered, and the reason is structural rather than discretionary.

Compounded drugs are not FDA-approved. The FDA states it directly: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." The agency adds that compounded drugs "should only be used in patients whose medical needs cannot be met by an FDA-approved drug."

That single fact is upstream of everything else on this page. Insurance coverage in the United States is built on top of FDA approval for a specific indication. Remove the approval and the coverage machinery has nothing to attach to. A prescription does not fix this. A doctor can lawfully prescribe a great many things a plan will not pay for.

Medicare Part D cannot pay for a pure compounded peptide, by definition.

The CMS Medicare Prescription Drug Benefit Manual, Chapter 6, section 10.4, sets out the rule for extemporaneous compounds: "only compounds that contain at least one ingredient that independently meets the definition of a Part D drug ... may be covered under Part D. Only costs associated with those components that satisfy the definition of a Part D drug are allowable costs under Part D because the compounded products as a whole do not satisfy the definition of a Part D drug."

The same section closes the other door: "Bulk powders (i.e., Active Pharmaceutical Ingredients for compounding) do not satisfy the definition of a Part D drug and are not covered by Part D."

A vial of compounded BPC-157 contains zero FDA-approved components. Under the manual's own arithmetic, the allowable cost is zero dollars. That is a definitional outcome, not a denial someone can appeal on the merits. Separately, Medicare's general exclusion at 42 U.S.C. section 1395y(a)(1)(A) bars payment for items and services that are "not reasonable and necessary for the diagnosis or treatment of illness or injury."

Commercial payers apply the same FDA-approval test to compounded drugs, and they publish it.

Cigna's drug coverage policy for compounded medications, IP0251, effective 15 December 2025, states that "Bulk chemicals used in compounded products do not meet the definition of a Prescription Drug in Cigna standard benefit plans." Its coverage criteria require, among other things, that "The compound must contain at least one FDA-approved prescription ingredient that is not otherwise excluded in the plan benefit language," and that the patient has already failed or cannot tolerate the FDA-approved alternatives. Anything outside those criteria is, in the policy's own words, "not medically necessary."

Aetna's Clinical Policy Bulletin 0170 covers the growth hormone question a different way. It lists indications Aetna considers "experimental, investigational, or unproven," and the list includes "Anti-aging" and "Anabolic therapy to enhance body mass or strength for professional, recreational or social reasons."

Two named policy documents, two different mechanisms, one outcome. Note what neither document does: neither names peptides as a class and bans them. The exclusion is upstream, in the definitions.

The peptides patients ask about were never legal to compound, and the 2026 FDA news did not change that.

Under Section 503A, a compounding pharmacy may only use a bulk drug substance that meets one of three conditions: it complies with a United States Pharmacopeia or National Formulary monograph, or it is a component of an FDA-approved drug, or it appears on the 503A Bulks List developed by the Secretary. Research peptides typically fail all three.

In September 2023 the FDA placed a set of peptides into "Category 2" of its interim compounding policy, defined as "bulk drug substances that may present significant safety risks." Its stated reasoning for BPC-157 is worth reading in full because it is a statement about missing evidence rather than proven harm: "Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans."

In April 2026 the FDA published a Federal Register notice and removed twelve peptides from Category 2, effective 23 April 2026. BPC-157, CJC-1295, epitalon, thymosin alpha-1, TB-500 and others now sit on the FDA's page under a heading reading "Bulk drug substances nominated but withdrawn." A great deal of online commentary read that as a green light. It is not one. As the FDA Law Blog put it, these peptides "were never listed in Category 1 and thus could not be legally used in compounding." Category 1 is the list that confers permission. Leaving Category 2 does not deposit a substance into Category 1; it removes it from a safety-concern list it was placed on after nominations were withdrawn. The legal status underneath is unchanged. We covered the specific case of one of these substances in the piece on whether BPC-157 is legal in 2026.

The July 2026 advisory vote is a recommendation, not a rule, and it would not create coverage either.

On 23 and 24 July 2026, the FDA's Pharmacy Compounding Advisory Committee considered seven peptides for addition to the 503A Bulks List and recommended six of them: BPC-157, KPV, TB-500, MOTS-c, epitalon and semax. Emideltide was voted down. Worth noting: the indications the committee actually evaluated were narrow clinical ones. BPC-157 was considered for ulcerative colitis. TB-500 and KPV for wound healing. MOTS-c for obesity and osteoporosis. Epitalon for insomnia. None of those are the anti-aging, recovery and longevity framings under which the substances are usually marketed.

The FDA's own page states that "Advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so." Formal notice-and-comment rulemaking would still be required, a process that ordinarily takes more than a year. The votes were close and were taken over two days: BPC-157, KPV, TB-500 and MOTS-c on 23 July, semax and epitalon on 24 July, with emideltide the single substance the committee declined.

And here is the part that matters for the insurance question specifically. Even a completed 503A listing would make a peptide legally compoundable. It would not make it FDA-approved. The Part D definition and the Cigna criteria both turn on FDA approval, not on compounding legality. A peptide could clear every hurdle in front of the FDA over the next two years and still be a cash-pay item on the day it clears them.

Some peptide drugs are FDA-approved, and those can be covered when medically indicated.

"Peptide" is a chemical description, not a regulatory category. Several peptide drugs carry FDA approval and are routinely covered when the patient meets criteria:

• Tesamorelin (EGRIFTA), a growth hormone releasing hormone analog, approved for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy.

• Teriparatide (FORTEO), a parathyroid hormone fragment, approved for osteoporosis in postmenopausal women at high risk of fracture, for men with primary or hypogonadal osteoporosis, and for glucocorticoid-induced osteoporosis.

• Octreotide (SANDOSTATIN), a somatostatin analog, approved to reduce growth hormone and IGF-1 in acromegaly where surgery or irradiation has not produced an adequate response.

• Leuprolide acetate (LUPRON DEPOT), a GnRH analog, approved for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty.

On growth hormone itself, one more piece of law is worth knowing. 21 U.S.C. section 333(e) makes it a federal offense, punishable by up to five years in prison, to knowingly distribute human growth hormone "for any use in humans other than the treatment of a disease or other recognized medical condition" authorized by the Secretary and ordered by a physician. The statute defines human growth hormone as "somatrem, somatropin, or an analogue of either of them." That reaches somatropin. It does not on its face reach secretagogues such as sermorelin or ipamorelin, which are not somatropin analogues. It is the reason a clinic cannot simply prescribe somatropin for anti-aging, and it is frequently misquoted as covering far more than it does.

The Endocrine Society's 2023 scientific statement Hormones and Aging is blunt on the underlying medicine: "No therapy to increase growth hormone secretion or action is currently approved as an anti-aging intervention, and the risks may outweigh the benefits."

The GLP-1 case proves the rule: coverage follows an approved indication, not a molecule.

Semaglutide and tirzepatide are peptides. Medicare Part D has statutorily excluded drugs used for weight loss since the benefit began in 2006. Then in March 2024 the FDA approved Wegovy for reduction of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity, and CMS confirmed that Part D plans may cover it for that indication. The molecule did not change. The approved indication did, and the coverage followed it.

That is the cleanest available illustration of why "will my insurance cover peptides" has no molecule-level answer. It has an indication-level answer, one drug at a time. For clinics running a GLP-1 program, the "is this right for me" question shows up on the very first call, which we worked through in the piece on handling the "is this right for me" first call at GLP-1 and peptide clinics.

HSA and FSA money can cover a prescribed peptide, but only as medical care for a diagnosed condition.

IRS Publication 502 defines the category narrowly: "You can include in medical expenses amounts you pay for prescribed medicines and drugs. A prescribed drug is one that requires a prescription by a doctor for its use by an individual." And on the other side: "Except for insulin, you can't include in medical expenses amounts you pay for a drug that isn't prescribed."

A compounded peptide dispensed on a valid prescription is a prescribed drug under that definition. The harder question is whether the treatment counts as medical care for a diagnosed condition rather than general wellbeing. Publication 502 draws that line explicitly for supplements: they are excluded "unless they are recommended by a medical practitioner as treatment for a specific medical condition diagnosed by a physician," because otherwise they "are taken to maintain your ordinary good health and aren't for medical care."

A Letter of Medical Necessity is a plan-administrator substantiation document. It is not an IRS-created exception, and Publication 502 contains no such provision. It can help document that an expense is medical care rather than general health. It cannot convert a non-qualifying expense into a qualifying one. Publication 502 also notes that in general you cannot include the cost of a prescribed drug "brought in (or ordered and shipped) from another country," which is relevant to anyone sourcing peptides overseas.

The office visit and the labs are a separate question from the drug.

Coverage is adjudicated per item and per service, not per appointment. An evaluation and management visit and medically necessary laboratory work can be billable even when the drug discussed at that visit is not covered. Aetna's own policy names the relevant codes, including 83003 for human growth hormone, 84305 for somatomedin (IGF-1), 80418 for the combined rapid anterior pituitary evaluation panel and 80428 for the growth hormone stimulation panel.

The distinction that decides the claim is intent. Those labs are covered when they are ordered to diagnose a condition, such as suspected adult growth hormone deficiency. They are not covered when they are ordered as a wellness panel to justify a cash protocol. Aetna expresses the same reasoning in its pediatric criteria: "further laboratory testing of children without classic GHD to diagnose 'partial' GHD, or other abnormalities of GH secretion or bioactivity, is considered not medically necessary." That criterion is written about children and is quoted here as an illustration of the reasoning, not as a rule governing adults.

For Medicare patients, there is a procedural step that often gets skipped. When a provider expects Medicare to deny an otherwise-covered item or service, an Advance Beneficiary Notice of Noncoverage, Form CMS-R-131, must be issued before the service is delivered. Skip it and the provider, not the patient, carries the liability. That is a financial-consent step, and it belongs in intake rather than at checkout.

Nobody publishes a credible price for compounded peptide therapy.

We looked. There is no peer-reviewed pricing survey, no GAO or KFF analysis, and no federal dataset covering direct-to-consumer peptide clinic pricing in the United States. Every dollar range in circulation traces back to a peptide seller, a clinic marketing page or an affiliate site. We are not going to pass those along, and a reader should treat any figure they find online the same way.

What can be sourced is the price of the FDA-approved comparators, through the CMS Medicare Part D Drug Spending Dashboard and the National Average Drug Acquisition Cost dataset. What cannot be sourced is the cash price of an unapproved compounded product, because the market that sets it is unregulated and unpublished. Our earlier piece on what peptide therapy costs works through the same problem from the patient's side. The parallel question in regenerative orthopedics, whether insurance covers PRP, resolves along the same lines and for related reasons.

The coverage question is a screening question, and a vague answer ends the call.

Everything above is regulatory. The operational consequence is not.

A prospective patient with a genuine interest in a peptide program almost always asks the insurance question first, and usually asks it on the phone, to whoever picks up. It is a screening question. She is deciding whether this is a conversation worth having. An answer of "I'm not sure, let me have someone call you back" reads as evasion on a subject where the caller is already primed to suspect she is being sold something.

A front desk that can say, clearly and in one breath, that the compounded protocol is cash-pay because it is not FDA-approved, that the consultation and diagnostic labs may be billable to her plan, and that certain FDA-approved peptide medications are a separate conversation, has answered the real question. The caller now knows what she is buying. That conversation happens at the front door or it does not happen at all. The same translation problem shows up when a caller cannot name the program she wants, which we covered in the piece on intake translation at longevity clinics.

This is the first of the Four Revenue Recovery Pillars, Zero-Miss Intake, in a narrow and specific form: inquiries arrive with a question the practice can answer, and reach nobody who can answer it. Aurora, our AI intake assistant for longevity and vitality practices (not a clinician), is built to answer exactly this call with the practice's approved coverage and payment information, and to route every clinical question to the clinical team.

Consider a Tuesday morning where every peptide inquiry from the weekend has already had the coverage question answered accurately, and the ones that stayed are on the consultation calendar with the financial expectation already set. That is an illustrative model of a well-instrumented intake layer, not a guarantee and not a client result.

Frequently asked questions

Will insurance cover peptides if my doctor prescribes them? Generally no. A prescription establishes that a licensed clinician ordered the drug. Coverage turns on whether the product is FDA-approved for the indication and, for a compound, whether it contains at least one FDA-approved prescription ingredient. A prescription alone satisfies neither test.

Is peptide therapy covered by Medicare? Not as a compounded product. The Medicare Prescription Drug Benefit Manual states that bulk active pharmaceutical ingredients used in compounding do not satisfy the definition of a Part D drug. FDA-approved peptide drugs such as teriparatide or tesamorelin are a different matter and can be covered when the patient meets the criteria.

Is BPC-157 covered by insurance? No. It is not FDA-approved, and it is not on the 503A Bulks List that would make it legal to compound. Its removal from the FDA's Category 2 list in April 2026, and the advisory committee's July 2026 recommendation, changed neither its approval status nor its coverage status.

Does insurance cover peptides for weight loss? Sometimes, for the FDA-approved GLP-1 medications, and only for an approved and non-excluded indication. Medicare Part D has excluded weight-loss-only drugs by statute since 2006; coverage opened for Wegovy specifically after its March 2024 approval for cardiovascular risk reduction. Commercial plan coverage varies considerably.

Is peptide therapy FDA approved? Some peptide drugs are. The compounded peptides marketed for recovery, anti-aging and performance are not. Those two facts are routinely blurred together in marketing copy.

Can I use my HSA for peptide therapy? Possibly, if the peptide is dispensed on a valid prescription and the expense is medical care for a diagnosed condition. IRS Publication 502 sets the standard. A Letter of Medical Necessity may support the claim but does not create an exception, and imported drugs are generally not includible.

Your clinic already gets this question. It also gets it on the phone rather than by email. And the caller is already deciding, in the first thirty seconds, whether you are a practice or a sales floor. Your calendar records the callers who booked. It records nothing at all about the ones who asked a question, did not get an answer, and hung up.

References

• U.S. Food and Drug Administration, Compounding and the FDA: Questions and Answers: fda.gov

• U.S. Food and Drug Administration, Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks: fda.gov

• Centers for Medicare and Medicaid Services, Medicare Prescription Drug Benefit Manual, Chapter 6, section 10.4: cms.gov

• Cigna Healthcare, Compounded Medications, Drug Coverage Policy IP0251, effective 15 December 2025: cigna.com

• Aetna, Clinical Policy Bulletin 0170, Growth Hormone and Growth Hormone Antagonists: aetna.com

• 21 U.S.C. section 353a (FD and C Act section 503A): govinfo.gov

• 21 U.S.C. section 333(e), distribution of human growth hormone: law.cornell.edu

• Internal Revenue Service, Publication 502, Medical and Dental Expenses: irs.gov

• The Endocrine Society, Hormones and Aging: An Endocrine Society Scientific Statement, 2023: endocrine.org

• Hyman, Phelps and McNamara, FDA Law Blog, on the April 2026 Category 2 removals and on day one of the July 2026 advisory committee (four substances): thefdalawblog.com

• ArentFox Schiff, "The (Pep)Tides Turn: FDA Panel Recommends Six of Seven for Compounding," covering both days of the July 2026 meeting: afslaw.com

• Fierce Pharma, "Peptide adcomm Day 2: Emideltide voted down in panel's 1st peptide pushback," 24 July 2026: fiercepharma.com

• U.S. Food and Drug Administration, Pharmacy Compounding Advisory Committee meeting page and materials, 23 and 24 July 2026, including the standing note that advisory committees make non-binding recommendations: fda.gov

• 42 U.S.C. section 1395y(a)(1)(A), Medicare exclusion for items and services that are not reasonable and necessary: law.cornell.edu

• FDA-approved prescribing information for EGRIFTA (tesamorelin), FORTEO (teriparatide), SANDOSTATIN (octreotide) and LUPRON DEPOT (leuprolide acetate), via Drugs@FDA: accessdata.fda.gov

• KFF, "A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesity," on the statutory Part D weight-loss exclusion and the March 2024 cardiovascular indication: kff.org

• Centers for Medicare and Medicaid Services, Advance Beneficiary Notice of Noncoverage (Form CMS-R-131): cms.gov

Zero-Miss Intake is the name of a design goal, not a guarantee that every call will be answered.

Next Step

If your premium practice runs more than 100 inbound consult inquiries a month and has no structured measurement of how many never reach a scheduled consultation, your pipeline may be leaking revenue you cannot see. The Line Audit shows you what actually happens: we call your line at the hours you're least likely to answer and send you the recordings with a written breakdown.

• Request The Line Audit: expand@thethinkingrobot.com

• Audit Real-Time Conversational Velocity: Talk to Rosey, our AI receptionist, at +1 (720) 776-1664 (an AI demo line; calls are recorded).